NEW YORK (GenomeWeb News) —Caprotec Bioanalytics has tapped Funakoshi to market and sell its research products in Japan, the Berlin-based company said today.

Under an exclusive agreement, Funakoshi will distribute Caprotec products based on its Capture Compound Mass Spectrometry technology. The CCMS technology consists of small, tri-functional molecules that are used to isolate proteins from biological samples, which are then identified and characterized by mass spectrometry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.